[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graft-versus-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graft-versus-leukemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":4,"leadSponsor":42,"locationsCount":45},"100054545","improved-methods-of-cell-selection-for-bone-marrow-transplant-alternatives-100054545",false,"NCT00001529","Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation","* INCLUSION CRITERIA:\n* Healthy individual aged 18 to 60 years.\n* No active infection or history of recurrent infection.\n* Normal renal function: creatinine \\\u003C1.5 mg\u002FdL or estimated glomerular filtration rate (eGFR) \\>=60 mL\u002Fmin\u002F1.73 m\\^2, with no significant proteinuria.\n\nNormal liver function: bilirubin \\\u003C2.0 mg\u002FdL (when unconjugated), transaminases \\\u003C2.0x ULN in the absence of known liver disease.\n\nNormal blood count: WBC 2,500-11,000\u002Fmicroliter, ANC \\>1,500\u002Fmicroliter, platelets \\>150,000\u002Fmicroliter, hemoglobin \\>12.0 g\u002FdL.\n\n* Normal cardiovascular function, no history of chest pain, myocardial infarction, peripheral vascular disease, transient ischemic attack, or stroke.\n* Healthy female subjects of childbearing age should have a negative serum pregnancy test with one week of beginning G-CSF administration.\n* Female subjects should not be lactating.\n* Subject must be eligible for normal blood donation. He or she must be tested negative for syphilis (RPR), hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV, HTLV-1, West Nile virus, T. Cruzi and Babesia test.\n* Subject must be able to comprehend the investigational nature of the study and provide informed consent to participate in the protocol.\n* Antecubital veins must be adequate for peripheral access during apheresis. Potential participants must be screened by an apheresis nurse to check venous access before protocol entry.\n\nEXCLUSION CRITERIA:\n\n* Active viral, bacterial, fungal or parasite infection.\n* Female with positive pregnancy test or lactating.\n* Active or moderate-to-severe autoimmune disease that is currently treated or expected to require immunosuppressive therapy. Candidates with stable, well-controlled mild autoimmune disease may be considered on a case-by-case basis.\n* Active or recent malignancy within the past 5 years. Individuals with remote (\\>5 years) histories of low-risk malignancies in remission (e.g., localized prostate cancer) or treated basal cell carcinoma may be included.\n* History of any hematologic disorders.\n* History of clinically significant cardiovascular disease (e.g., symptomatic coronary artery disease, uncontrolled hypertension). Minor risk factors must be evaluated on a case-by-case basis (e.g., controlled hypertension).\n* Any positive serum screening test as listed in eligibility.\n* Allergy to G-CSF or bacterial E coli products.\n* Administration of NSAID within. 5-7 days of starting the protocol, depending on drug half-life.\n* History of G-CSF administration and leukapheresis within past 3 months.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old.\n\nOne serious reaction complicating bone marrow transplants is referred to as graft-versus-host disease (GVHD). GVHD is a potentially fatal incompatibility reaction. The reaction is caused by antigens found on the cells of the patient that are not present on the cells of the donor. The antigens are recognized by transplanted white blood cells (lymphocytes). These lymphocytes begin attacking the recipient s cells and tissues and may lead to death.\n\nIn order to avoid GVHD, researchers have developed a technique using peripheral blood instead of bone marrow that allows transplantation of stem cells and removal of lymphocytes. Stem cells are the cells responsible for returning blood cell production to normal. Lymphocytes are the white blood cells that can cause GVHD.\n\nThe technique requires two steps. In the first step blood cells are collected from donors who have received doses of a growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells.\n\nIn the second step white blood cell lymphocytes are removed from the collected blood, leaving only the stem cells.\n\nThe main goal of this study is to develop and improve the method of processing cells that are collected after stimulation with growth factor (G-CSF), by removing the white blood cell lymphocytes which can cause graft-versus-host disease (GVHD) while keeping the stem cells necessary for healthy blood cell building. In addition, researchers are interested in studying whether giving G-CSF has an effect on lymphocyte function, which may influence the immune reactions occurring in bone marrow transplantation.",[26,27,28],"Graft-Versus-Host Disease","Graft-versus-leukemia","Donor Apheresis",[30,28,31,32,33,34],"G-CSF","Graft Versus Host Disease","graft versus leukemia","Natural History","Normal Volunteer","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"1996-03-18",{"name":43,"class":44},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":45},"100065731","long-term-evaluation-and-follow-up-care-of-patients-treated-with-stem-cell-transplants-100065731","NCT00106925","Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","Long-Term Evaluation and Follow Up Care of Patients Treated With Allogeneic Stem Cell Transplants","* INCLUSION CRITERIA-TRANSPLANT RECIPIENTS:\n\nPatients surviving three years or more from date of first stem cell transplant who have been treated.\n\n-With an experimental allogeneic stem cell transplant on a NHLBI HB protocol\n\nOr\n\n-With a standard of care allogeneic stem cell transplant on an NHLBI protocol\n\nOr\n\n-Selectively, when the allogenic transplant was conducted outside the NIH, but the subject has a special condition of interest to the research team\n\nAge greater than or equal to 7 years old and age less than or equal to 80\n\nFor adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.\n\nEXCLUSION CRITERIA-STEM CELL TRANSPLANT RECIPIENTS:\n\nNone, all patients meeting the inclusion criteria will be eligible","7 Years","80 Years",{"count":56,"type":22},1000,"This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant.\n\nPatients between 10 and 80 years of age who received a donor stem cell transplant at the NIH Clinical Center under an NHLBI protocol may be eligible for this study. Candidates must have had their first transplant at least 3 years before entering the current study.\n\nParticipants are generally seen in the clinic every 12 months for some or all of the following procedures:\n\n* Periodic physical examinations, eye examinations, and blood and urine tests.\n* Bone marrow aspiration and biopsy: A sample of bone marrow is obtained for microscopic examination. The patient is given local anesthesia or conscious sedation. An area of the hipbone is numbed, a thin needle is inserted through the skin into the bone, and a small amount of marrow is withdrawn.\n* Tissue biopsy: A small piece of tissue or tumor is obtained for microscopic examination. Depending on the site of the biopsy, the tissue may be removed using a cookie cutter-like \"punch\" instrument, a needle, or a knife. The area is numbed and the tissue is removed with the appropriate tool.\n* Imaging tests to visualize organs, tissues, and cellular activity in specific tissues. For these tests, the patient lies on a table that slides into the scanner. They may include the following:\n\n  1. Nuclear scans use a sensitive camera to track a small amount of radioactive material (radioisotope) that is given to the patient by mouth or through a vein. The scan may show abnormal areas of tissue in the bones, liver, spleen, kidney, brain, thyroid, or spine.\n  2. Magnetic resonance imaging (MRI) uses a magnetic field and radio waves to examine small sections of body organs and tissues.\n  3. Computerized tomography (CT) uses x-rays and can be done from different angles to provide a 3-dimensional view of tissues and organs.\n  4. Positron emission tomography (PET) uses a fluid with a radioisotope attached to it to show cellular activity in specific tissues. The fluid is given through a vein and travels to the cells that are most active (like cancer cells), showing if there is an actively growing tumor.\n* Pulmonary (lung) function tests: The patient breathes into a machine that measures the volume of air the person can move into and out of the lungs.\n* Heart function tests may include the following:\n\n  1. Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on the chest transmit information from the heart to a machine.\n  2. Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the heart and examine the function of the heart chambers and valves.\n  3. Multiple gated acquisition scan (MUGA) is a nuclear medicine test that uses a small amount of radioactive chemical injected into a vein. A special scanner creates an image of the heart for examining the beating motion of the muscle.\n\nDisease relapse or progression, or transplant-related problems may be treated with standard medical, radiation, or surgical therapy, or patients may be offered experimental therapy.",[27,59,60],"Graft vs Host Disease","Graft Rejection",[62,63,31,64,65,33],"Peripheral Blood Stem Cells","Graft Versus Leukemia\u002FMyeloma","Whole Body Irradiation","Leukemic Relapse","2026-06-03",{"date":68,"type":39},"2026-06-04",{"date":70,"type":39},"2005-04-22",{"name":43,"class":44}]